KYAN Technologies to Present New Data on Optim.AI™ Immunotherapy and Real-World Pan-Cancer Utility at AACR 2025
Data shows validation of FPM platform in breast cancer immunotherapy and 85% clinical concordance across over 20 solid cancers and hematologic malignancies. SINGAPORE, SINGAPORE, SINGAPORE, April 19, 2025 /EINPresswire.com/ -- KYAN Technologies …